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L2PB1 CELL DEPLETION WITH DIPHTHERIA TOXIN IN PD-L2 KIKO MICE 
REBECCA ARWYN LEE 
 
ABSTRACT 
As we learn more about immune cell subpopulations, we find an increasingly 
complex system of cells with diverse functions. L2pB1 cells are a PD-L2 positive B1a B 
lymphocyte subpopulation that has unusual properties and characteristics that are not 
fully understood by many. By creating and implementing a transgenic mouse model that 
allows for targeted depletion of this specific group of cells, we can further elucidate their 
physiological functions and roles in both healthy and diseased states. 
 Here we demonstrate the depletion of L2pB1 cells utilizing a transgenic mouse 
model expressing Diphtheria Toxin Receptors on their surface. After a course of 4 
injections of 25ng of Diphtheria Toxin per gram bodyweight, we observed a successful 
depletion of L2pB1 cell population.  Further studies are underway investigating the 
effects of a high fat diet on these L2pB1 depleted mice.  
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INTRODUCTION 
The immune system is of such a complicated intellectual design, that despite two 
centuries of research, we still cannot fully harness nor even appreciate the full power of 
immunity. Mouse models have contributed vastly to our understanding of the 
physiological roles and functions of immune component and provide the basis for human 
study and application. 
B cells were primarily thought to produce antibodies for defense against 
infectious pathogens and act as memory cells, which responded to subsequent infections. 
More and more evidence has indicated that B cells are also major players in maintaining 
tissue homeostasis. Different types of B cells have been discovered to possess a repertoire 
of immune functions and can be identified by their surface markers. L2pB1 cells are a 
unique subset of B cells that are of particular interest due to their unusual and powerful 
characteristics. In this project, we investigated the physiological functions of L2pB1 cells 
by using a transgenic mouse model allowing for targeted depletion of L2pB1 cells in diet-
induced-obese mice.  
 
What are B cells? 
B cells are broken up into two major groups: B2 B cells and B1 B cells. B2 B 
cells are the conventional B cells present in the follicular and marginal zone. B1 cells can 
be found primarily in the peritoneal and pleural cavity, as well as in smaller 
concentrations in the lymph nodes and spleen (Kantor, 1993). Despite being a small 
population of cells, B1 cells produce the majority of naturally circulating IgM, which is 
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essential in the response to initial infection (Moon, 2011). B1 cells are unique in that 
during their development, self-reactive B1 cells undergo positive selection (Baumgarth, 
2011). The ability of B1 cells to produce natural antibody allows for innate immune 
protection from infections. Additional functions include maintenance of gut microbe 
homeostasis and clearance of apoptotic cells (Baumgarth, 2011). Furthermore, B1 cells 
originating in the peritoneal cavity have also been shown to have the ability to 
phagocytize bacteria, lipids, polystyrene microspheres, and phosphatidylcholine (Gao, 
2012) (Vo, 2014). These phagocytic properties of B1 cells demonstrate a macrophage-
like ability in this cell population and the immune surveillance these cells provide.  
B1 cells are further broken up into B1a cells that express CD5 and B1b cells that 
do not express CD5 (Baumgarth, 2011). B1a cells have been shown to produce over 80% 
of the naturally circulating IgM (Vas, 2013). This demonstrates the importance of B1a 
cells in the innate immune response. Self-reactive B1 cells have been shown to recognize 
phosphatidylcholine (PtC) as well as phosphorylcholine (PC) heads (Kantor, 1993). 
These Anti-PC B cells have also been identified in humans and the quantity of these cells 
have been found to correlate to measured serum Anti-PC levels (Fiskesund, 2014). 
 
What are L2pB1 Cells? 
CD5 positive B1a B cells can be further broken up into PD-L2 positive cells, 
known as L2pB1 cells, which are primarily found in the peritoneal cavity and make up 
50-70% of peritoneal B1a cells (Zhong, 2011) (Zhong, 2007). L2pB1 cells can also be 
found in small numbers in the spleen and lymph nodes of mice (Zhong, 2007). PD-L2 is a 
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ligand that interacts with PD-1, a programmed death molecule involved in attenuating 
immune responses (Ghiotto, 2011). Antigen presenting cells from PD-L2 deficient mice 
display an enhanced T-cell activating potential both in vitro and in vivo (Zhang, 2006). 
Experimental autoimmune	  encephalomyelitis (EAE) shows increased disease severity 
when PD-L2 is blocked at either the initiation or chronic phase of the disease (Salama, 
2003) (Zhu, 2006). These reports suggest that PD-L2 may have a physiological role of 
dampening and regulating T-cell-mediated inflammatory immune responses. This may 
very well be an important function of PD-L2 expression on L2pB1 cells.  
 Since L2pB1 cells share most of the surface markers with L2nB1 cells except for 
PD-L2 expression, it is very difficult to sort out L2pB1 cells without using an anti-PD-L2 
antibody, which may block and interfere with its function. In order to avoid blocking the 
PD-L2 molecule on L2pB1 cells, an endogenous labeling system to track and sort out 
L2pB1 cells is needed. The fact that PD-L2 is expressed on activated macrophages, 
dendritic cells, and some other cells makes it extremely challenging to specifically track 
or delete PD-L2+ B cells by targeting PD-L2 molecule. 
L2pB1 cells share many of the same properties as B1 cells including IgM 
secretion, expression of IL-10, and also affect the differentiation of T cells. L2pB1 cells 
are additionally known for their ability to recognize and produce antibodies against 
phosphorylcholine (PC) and may be the primary B1 cell type binding PC (Zhong, 2011). 
L2pB1 cells can also stimulate T cells and induce Th17 cell differentiation, which can 
potentially lead to pro-inflammatory Th1 and Th17 cells (Zhong, 2011). The potential 
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protective as well as pathogenic properties of L2pB1 cells require continued 
investigation. 
 
Past models relevant to elucidating the role of L2pB1 cells 
Bnull mice are an example of knock out mice that have been used to study the 
effects of B cells in diseased states. In previous studies, Bnull mice were given a high fat 
diet (HFD) and developed type 2 diabetes. In these mice, it was found that IgG producing 
B cells were pathogenic in the development of glucose intolerance and insulin resistance 
(Winer, 2011).  
B cell lineage ablation through the administration of antibodies is another method 
of studying the role of B cells in mouse and humans. However, this technique has varying 
effects, may only allow for partial deletion, and the exact mechanisms by which they act 
are not fully understood (Bush, 2005). Pan-B cell depletion through this method has been 
used as treatments in autoimmune disease and lymphomas (Buch, 2005). However, such 
depletion cannot distinguish B1 and B2 B cell functions and physiological roles in 
diseases. 
Fortunately, the utilization of a Cre recombinase inducible expression of 
Diphtheria Toxin Receptor (DTR) expression on the surface of a cell type can allow for 
ablation of a specific cell type through a well-established mechanism of Diphtheria Toxin 
mediated cell death (Bush, 2005). DT acts by inhibiting protein synthesis and causing 
apoptosis of the cell expressing Diphtheria Toxin Receptor (DTR), while wild-type cells 
in mice remain unharmed (Saito, 2001). 
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Transgenic mice with an inserted DTR on B cells have been successfully 
demonstrated. Demircik et al. reported that Diphtheria Toxin can deplete B cell 
populations in CD19-Cre mice that were crossed with the iDTR. It was found that after 
25ng DT/gram bodyweight dosages for 4 days, the mice had 99% depletion of total B 
cells. However, immature B cells in the bone marrow do not yet express CD19 and 
therefore were not completely depleted. Immunoglobulin (Ig) levels were measured each 
week by blood drawing for the 5 weeks following DT application. They found that during 
the 5 weeks, serum IgK, IgM and IgG1 levels were reduced. They also looked at the 
plasma cells population in bone marrow 4 weeks after the B cells were depleted with DT. 
They found a reduction of the plasma cells in the bone marrow from 8% to 1% 
(Demerick, 2013).  
By creating a mouse that expresses the DT receptor on the surface of its L2pB1 
cells, this population of cells can be effectively depleted at specific time points in order to 
visualize changes that may occur immunologically or physiologically in the mouse. 
Targeted depletion of L2pB1 cells through the expression of DTR opens up a multitude 
of potential research applications in investigating their effects throughout the body and in 
different diseases. 
 
HFD, Obesity, and B cells: 
Obesity has become a growing concern throughout the world and is the cause of 
many diseases such as diabetes, atherosclerosis, arthritis, and liver disease (Grant, 2015). 
Currently approximately 16.9% of youth and 34.9% of adults in the United States are 
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obese (Ogden, 2014). With such a large population at risk for obesity related illness, it is 
essential to investigate not only the epidemiological impact of obesity, but also the 
immunological response.  
Winer et al. reported that in HFD mice, an increased number of B cells, T cells, 
and class switched mature IgG positive B cells were observed, suggesting an autoimmune 
response to HFD. They also showed that Bnull mice were protected against insulin 
resistance and decreased glucose tolerance. B cells can act locally in VAT to activate T 
cells, increase pro-inflammatory cytokines and mediators such as TFN alpha, and affect 
M1 macrophage polarization. They can also act systemically to produce pathogenic IgG, 
hinder glucose metabolism, as well as promote insulin resistance (Winer 2011). 
However, B regulatory cells producing IL-10 found in adipose tissues, have been 
shown to be protective against insulin resistance (Nishimura, 2013). B1a cells have 
distinctly powerful characteristics that could aid in diseased states in which inflammation 
plays a role. B1a cells been shown to reduce inflammatory cytokines and potentially help 
attenuate the progression of atherosclerosis (Hosseini, 2015). There has also been 
evidence that B1a cells can act to attenuate insulin resistance in HFD-fed mice through 
their production of IL-10 and IgM, while B2 cells appear to have pathogenic roles in 
HFD mice (Shen, 2015). Aside from their secretory roles, B1 B cells’ phagocytic 
potential can be further activated in obesity states in which they present with enlarged 
cytosols and macrophage-like characteristics. However, these phagocytic properties differ 
distinctly from macrophages in that there is specific recognition of PtC coated beads by 
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B1 B cells, which then deviates to non-specific phagocytosis under high fat diet 
conditions (Vo, 2014). 
The both secretory and phagocytic properties of B1 cells have contributed to a 
greater understanding of their roles in obese states and diabetes. However, further 
research is needed to determine the role of distinct subpopulations as well as their 
mechanisms of action. Once this information can be elucidated, it can open doors up for 
potential additional therapeutic interventions in multiple diseases.  
 
Our Mouse Model: 
For the past 6 years, Dr. Zhong’s lab has been working to create a mouse model 
that can specifically be used to study PD-L2+ B1 B cells in vivo. To solve the difficulty 
of tracking L2pB1 cells, we have generated a PD-L2-ZsG-TdT-DTR Knock-In (KI) and 
inducible Knock-Out (KO) mouse model (Figure 1). A ZsGreen fluorescent protein gene 
was inserted downstream of PD-L2 gene and was floxed for Cre DNA recombinase-
induced depletion. A TdTomato fluorescent protein gene was also inserted downstream 
of PD-L2-ZsGreen gene separated by stop codon. Such arrangement allows the 
expression of ZsGreen gene in all cells that express PD-L2.  
Upon crossing to CD19-Cre KI mice, all CD19-expressing B cells will deplete 
ZsGreen gene and express TdTomato gene. All other PD-L2-expressing cells will remain 
expressing ZsGreen. In this way, L2pB1 cells can be tracked as TdTomato-expressing 
cells in the peritoneal cavity and abdominal fat tissue. Sorting L2pB1 cells will be 
possible without blocking PD-L2 function by FACS-staining with anti-PD-L2 antibodies. 
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More importantly, a Diphtheria toxin receptor (DTR) gene is inserted under TdTomato 
gene so that upon IP injection of Diphtheria Toxin, L2pB1 cells will be specifically 
depleted. After 4 years of design, cloning, microinjection and breeding, we finally 
obtained a germ-line transmitting line (Figure 1A, B). We have obtained both 
heterozygous and homozygous littermates (Figure 1C).  
 Interestingly, PD-L2-ZsGreen expression is mono-allelic (Figure 1D). In 
heterozygous mice, L2pB1 cells either express the KI allele or WT allele, but not both 
(Figure 1D). Such mono-allelic expression patterns have been reported for many cytokine 
genes (Hollander, 1998) (Bayley, 2003) (Mostoslavsky 2004) (Bouabe, 2012). This 
would be problematic in cytokine knock-in reporter mice where the reporter gene 
replaces the cytokine gene. In those cases, there would be false positive or false negative 
cells in heterozygous mice where either cytokine (WT allele) or reporter gene (KI allele) 
is expressed. However, it will not be any problem in our animal model, as PD-L2 
expression is not disrupted by ZsGreen insertion and both PD-L2 and ZsGreen are 
expressed in the KI allele. Thus, when there is ZsGreen expression, there must be PD-L2 
expression. This is the advantage of our design over traditional KI reporter mice. 
In order to detect the knock in and wild type alleles, two probes were designed 
(Figure 1B). This was accomplished through the digestion of genomic DNA through 
BAMHI and Mfel. PCR primers were also designed for DNA genotyping of tail samples. 
WT (-/-) fragments of 228bp were amplified and 285bp fragments were amplified from 
the (+/+) mutant mouse (Figure 1C). The sequences of the primers are as follows: PD-L2-
A1 LoxP-F primer (-GCAGAGTCTAGGCTCTTGAGTTC-) and the PD-L2-A2 LoxP-R 
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primer (-AGCAGGTGATTCAGCTATGATGC-). Heterozygous mice display both 
bands.   
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Figure 1A: Transgenic Mouse Design. ZsGreen is a cDNA copy of green fluorescent 
protein (GFP) which was inserted after the stop codon in exon 5 (Yellow bar) of PD-L2 
gene separated by an internal ribosome entry site (IRES). BGHPA sequences and a 
Neomycin resistant gene (Neo) and a were inserted after exon 6 (Blue bar). 2 LoxP 
sequences flanked these insertions (Blue triangles). A duplication of exon 5 was inserted 
after the 3’ end LoxP sequence. A cDNA copy of Diphtheria toxin receptor (DTR) and an 
IRES were inserted after the stop codon in the duplicate exon 5, followed by a cDNA 
copy of red fluorescent protein, TdTomato. DTR and TdTomato genes were separated by 
a 2A sequence. The sequence flanked by the LoxP sites will be permanently removed 
following the cross to a Cre recombinase transgenic mouse. This will leave only IRES-
DTR-2A-TdTomato sequence.  
Subsequently, TdTomato will indicate PD-L2 expression specific to B cells. B 
cells expressing PD-L2 will be red, while macrophages and dendritic cells will remain 
green. This also allows us to determine the effects of B cells that express PD-L2 by 
injecting DT and therefore deleting these specific cells through their additional 
expression of DTR, while sparing the non-B cell populations that express PD-L2.  
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Figure 1B: Probe design used in the detection of knock in alleles and wild type 
alleles.  
 
 
Figure 1C: PCR primers designed for DNA genotyping. Tail DNA was extracted for 
PCR amplification. WT (-/-) fragments of 228bp were amplified and 285bp fragments 
were amplified from the (+/+) mutant mouse. Heterozygous mice display both bands.  
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FACS analysis of littermate mice was performed on a wild type (WT) (-/-), a 
heterozygous (+/-) and a homozygous (+/+) PD-L2-ZsG-TdT-DTR knock-in littermates. 
Monocytes including peritoneal T cells, B1 B cells, and B2 B cells were gated according 
to B220, CD5 and IgM expression. ZsGreen is only expressed by L2pB1 cells in +/- and 
+/+ mice (red arrow) but not WT L2pB1 cells.  
WT (-/-), heterozygous (+/-), and homozygous (+/+) PD-L2-ZsG-TdT-DTR 
knock-in litter mates (Figure 1E). B220, CD5, and IgM expression were used to gate 
monocytes such as B2 B cells, B1 B cells, and peritoneal T cells. ZsGreen expression is 
only seen in the L2pB2 cells +/+ and +/- mice (seen as a red arrow), while ZsGreen is not 
seen in the WT L2pB1 cells. Similar patterns have been seen in L2pB1 cells in the 
thymus, spleen, etc. 
The fluorescence of the L2pB1 cells was also visualized using a Leica 
microscope. Peritoneal cells were isolated from CD19-Cre(-/-)/PD-L2(+/+) mice via a 
peritoneal cell washout (PCW) (Figure 2A). CD19 positive cells are seen in blue. Cells 
that fluoresce green indicate the presence of ZsGreen. These cells do not express 
TdTomato because they are Cre negative cells. The overlay indicates the cells expressing 
both CD19 (blue) and PD-L2 (green), which can be identified as L2pB1 cells. We then 
isolated peritoneal cells from CD19-Cre(+/-)/PD-L2(+/+) mice (Figure 2B). CD19 cells 
are shown in blue. ZsGreen expression is not shown in these mice because the presence 
of Cre masks ZsGreen and instead, PD-L2 express TdTomato (red). As seen in the 
overlay, mice with this phenotype possess L2pB1 cells that express TdTomato on the 
CD19 positive cells.  
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Figure 1D: FACS analysis of a wild type (WT) (-/-), a heterozygous (+/-) and a 
homozygous (+/+) PD-L2-ZsG-TdT-DTR Knock in littermates. Peritoneal T cells, B1 
B cells, B2 B cells were gated according to B220, CD5 and IgM expression. ZsGreen is 
expressed only by L2pB1 cells in +/- and +/+ mice (red arrow) but not WT L2pB1 cell. 
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Figure 1E:  FACS analysis: WT (-/-), heterozygous (+/-), and homozygous (+/+) PD-
L2-ZsG-TdT-DTR knock-in. B2 B cells, B1 B cells, and peritoneal T cells were 
distinguished by gating the monocytes on B220, CD5, and IgM expression.  ZsGreen 
expression is only seen in the L2pB2 cells +/+ and +/- mice (seen as a red arrow), while 
ZsGreen is not seen in the WT L2pB1 cells.   
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Figure 2A: Peritoneal cells CD19-Cre(-/-)/PD-L2(+/+) mice.  CD19 positive cells 
(blue). The overlay indicates the cells expressing both CD19 (blue) and PD-L2 (green), 
which can be identified as L2pB1 cells.  
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Figure 2B: Peritoneal cells from CD19-Cre(+/-)/PD-L2(+/+) mice.   CD19 cells (blue). 
TdTomato (red).  As seen in the overlay, mice with this phenotype possess L2pB1 cells 
that express TdTomato on the CD19 positive cells.  
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RESULTS AND DISCUSSION 
ELISA: 
Following depletion of L2pB1 cells, we measured circulating natural antibody 
levels using a monoclonal antibody E06 as the standard. E06 will bind to oxidized 
phospholipid’s PC head group {Technical data sheet for Avanti). Because the half-life of 
IgM in adult mice has been determined to be approximately 2 days (Vieira, 1988), we 
decided to collect serum samples 4 days after the first injection as well as 7 days after the 
first injection in order to visualize the decrease in Anti-PC IgM levels following 
depletion. 
Serum Anti-PC IgM levels were found to decrease in mice after receiving 
injections of 25ng/g of DT for 4 consecutive days (Figure 3A). On the 4th day after 
receiving the first injection, mice receiving injections of DT were observed to have an 
Anti-PC IgM serum level 52.4% of the pre-injection reading, while control mice 
(received injections of PBS) were observed to have serum readings that were 83.4% of 
the original (n=5, p=0.001). 7 days after the 1st injection (3 days after receiving the 4th 
and final injection), the mice that had received DT showed Anti-PC levels that were 
38.2% of the pre-injection readings, while control groups had 79.5% of Anti-PC IgM 
levels of their pre-injection readings (n=5, p=0.0004). The slight decrease in readings 
observed in the control mice was likely due to day-to-day fluctuations in Anti-PC IgM 
levels in the serum. 
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Figure 3A: Change in Anti-PC IgM Level As A % Of The Pre-Injection Reading.  
Serum Anti-PC IgM levels decreased after DT injection regimen. Day 4 post 1st injection 
*(n=5, p=0.001).   Day 7 post 1st injection **(n=5, p=0.0004).  
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We then wanted to investigate the long-term effects of L2pB1 cell depletion with 
DT. Mice were injected with the same DT regimen as before and blood samples were 
taken at 4, 7, 10, 14, 21, 35, 49, and 70 days following the first injection. An Anti-PC 
IgM ELISA was performed on a group of mice 70 days (10 weeks) after receiving a 
treatment of DT or PBS (control) (Figure 3B). Control mice were injected with PBS and 
were used to normalize for natural fluctuations of serum Anti-PC IgM levels. Serum 
Anti-PC IgM levels found to have deviated enough between the two test groups to 
achieve a statistical significance of p=0.05 at Day 7, p=0.002 at Day 10, and p=0.05 at 
Day 21. This demonstrated a significant decrease in L2pB1 cell population and the 
production of Anti-PC IgM. Differences between the groups continue to be seen all the 
way through the 10th week post injection, however, we are not able to calculate statistical 
significance. This is likely due to the small sample size of n=2 for each group. In the 
future, it would be beneficial to enlist more mice in this long term tracking of Anti-PC 
IgM serum levels in order to further clarify the differences between the groups. While 
serum Anti-PC IgM levels remained depressed between 20-40% of original levels 
throughout the 10 weeks, we saw slight increases in serum levels during the time course.   
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Figure 3B: Change in Anti-PC IgM Level (% of Pre-Injection Reading) 10 weeks. 
Mice were given a course of 4 injections of DT or PBS (Control).  Serum samples were 
then collected for the following 10 weeks. n=2, p=0.05 (Day 7), p=0.002 (Day 10), and 
p=0.05 (Day 21). 
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To investigate the role that HFD plays in Anti-PC IgM levels, additional mice 
were recruited. Mice were given the same standard 4-injection course of DT or PBS 
(Control) and were monitored. At week 1 following the first injection, there was a 
significant difference in Anti-PC IgM serum levels between the DT group and the 
Control group (Figure 3C, n=3, n=2, p=0.003). However, this difference in measured 
serum levels decreased as time progressed and both groups were observed to have 
declining Anti-PC IgM serum levels (data not shown). Further studies need to be 
completed to assess the long-term effect of HFD on L2pB1 cell depleted mice. 
This observed loss of significance in both the normal diet and HFD studies 
between the DT and Control group could be due to replenishment of the L2pB1 cell 
population. L2pB1 cells may have proliferated as a feedback response to the depletion, 
which would then cause a return of Anti-PC IgM levels. Another possibility is that the 
L2pB1 cell population was partially restored by the bone marrow generating additional 
cells. Additionally, depletion of L2pB1 cells could have instigated a compensatory action 
by alternative B cells that may have been able to produce PC recognizing IgM.   
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Figure 3C: Change in Anti-PC IgM Level (% Of Pre-Injection Reading) For Male 
Mice On HFD). DT mice (n=3) and Control mice (n=2) were sampled at week 1, week 
3, and week 5 following the first injection of DT. Decreases in Anti-PC IgM levels are 
visualized for both groups. At 1 week post injection, there is a significant decrease in 
Anti-PC IgM serum levels in the mice that received DT injections *(p=0.003). 
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FACS: 
FACS analysis was performed on PCW samples from Control and L2pB1 cell 
depleted mice (DT injected mice). Cells were gated on CD19 and PD-L2. Control mice 
were seen to have approximately 12.4-15.3% L2pB1 cells, while DT injected mice were 
seen to have 0.74-0.86% L2pB1 cells (Figure 4A). Approximately 95% of L2pB1 cells 
were depleted within 1 week after the first injection of DT. 
We then investigated the long-term cell population effects of DT depletion 
through FACS analysis. 10 weeks following the first injection, mice were sacrificed and 
PCW samples were collected. PD-L2 positive B1 cells (L2pB1 cells) were seen to be 
approximately ¼ that of baseline levels at 10 weeks (Figure 4C). It appears that due to the 
self-regenerative abilities of these cells, there was some return in the cell population over 
the time course.  
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Figure 4A: FACS Results of PCW Samples Gated on CD19 and PD-L2. 2 Control 
mice received PBS injections while DT injected mice received DT injections. 1 week 
following the 1s injection mice were sacrificed and PCW cells were collected. L2pB1 
cells were gated as CD19+ and PD-L2+ seen in the upper right quadrants. Near complete 
depletion of L2pB1 cells were observed 
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Figure 4B: PD-L2+ ZsGreen+ and PD-L2+ TdTomato+ cell distribution.  PCW 
samples were collected 10 weeks following the 1st injection and FACS analysis was run. 
Gating was done as follows: 
B1: CD5MedB220MedCD19+IgM+  
B2: CD5-B220HighCD19+IgM+ 
Microphage: CD5-B220- 
T:   CD5+B220- 
B1 cells were seen to have be approximately 20-25% that of baseline levels, indicating 
some regrowth of the cell population. 
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 We then wanted to investigate the roles of L2pB1 cells in weight gain in HFD 
mice. Mice were weighed at weekly intervals following 4 weeks on HFD (Figure 5). It 
was observed that male and female mice gained weight at different rates, with male mice 
gaining significantly more weight than females. In order to establish consistency in 
weight gain observation, male mice were used for weight gain analysis. Within 4 weeks 
on a 60% Fat/Cal diet, a 50% increase in bodyweight was observed. By 7 weeks on HFD, 
mice who had received an injection course of DT experienced on average a 75.3% gain in 
bodyweight, while mice who had received injections of PBS were observed to gain 
58.9% in bodyweight. These preliminary data show that L2pB1 depleted mice gained 
slightly more weight than mice than control mice also on HFD. However, due to 
individual differences in weight gain and rate, larger sample sizes are needed to confirm 
weight differences between these two groups.  
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Figure 5: % Bodyweight Gain Over Time. 3 male DT mice and 3 male PBS mice were 
weighed at weekly intervals following administration of DT/PBS and HFD initiation. 
Mice that received DT injections (L2pB1 cell depleted) appear to gain slightly more 
weight during the first 7 weeks of HFD when compared to control mice.  
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 It has been well established that a HFD causes mice to develop glucose 
intolerance, insulin resistance, and ultimately diabetes. We then looked at the effect 
L2pB1 cells’ depletion has on glucose tolerance in HFD mice. Previous data show 
glucose tolerance to become impaired as early as 7 weeks (data not shown).  
We performed a preliminary glucose tolerance test at 5.5 weeks to investigate 
whether the DT injection group had begun to deviate from the PBS injected group 
(Figure 6A). This glucose tolerance test was performed on 3 male DT mice and 5 male 
PBS injected mice and showed varying responses to administration of glucose. It appears 
that L2pB1 cell depleted mice experienced a sharper spike in blood glucose levels as well 
as varying rates of return to baseline levels. Baseline blood glucose readings of DT 
injected mice were slightly higher than control groups. At 15 min after administration of 
glucose, mice that had received DT injections experienced a statistically significant 
difference in blood glucose levels.  
At 7.5 weeks on HFD, 3 DT injected male mice and 2 PBS injected male mice 
underwent another GTT.  Pre-injection blood glucose readings were relatively similar in 
both groups. Response to glucose administration followed a similar trajectory to the GTT 
performed at 5.5 weeks on HFD with the DT injected group climbing to higher blood 
glucose levels than the control group. At 15 min after glucose injection, there was a 
significant difference between the two group’s blood glucose readings. Additional mice 
are required to gather more data and further elucidate the effects of L2pB1 cells on 
glucose tolerance in HFD mice.  
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Figure 6A: Average Glucose Tolerance Test After 5.5 weeks on HFD: Glucose 
tolerance tests were performed after 5.5 weeks on HFD. At 15 min after administration of 
glucose, there is statistical significance p=0.009. Due to small sample size, we are not 
able yet to determine whether there is a conclusive difference between these two groups. 
0	  
50	  
100	  
150	  
200	  
250	  
300	  
350	  
400	  
0	  min	   15	  min	   30	  min	   45	  min	   60	  min	   75	  min	   90	  min	  
Bl
oo
d	  
Gl
uc
os
se
	  R
ea
di
ng
:	  m
g/
dl
	  
GTT	  At	  5.5	  Weeks	  on	  HFD	  Male	  Mice	  
DT	  Group	  
PBS	  Injected	  Group	  
*
	  	   30 
 
Figure 6B: Average Glucose Tolerance Test After 7.5 weeks on HFD. After 7 weeks 
on HFD, DT depleted mice show slightly higher blood glucose levels than the PBS 
injected group. n=3 DT injected, n=2 PBS injected *p=0.01.  Due to small sample size, 
we are not able yet to determine whether there is a conclusive difference between these 
two groups.   
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DISCUSSION 
For the first time, successful L2pB1 cell depletion has been demonstrated using a 
transgenic DTR model.  This method of depletion is especially useful in its potential 
future applications.  The ability to elucidate the various roles of L2pB1 cells has become 
simplified and streamlined. This mouse model has a wide range of applications, from 
diabetes and cardiovascular disease to cancer.   
Our L2pB1 cell depleted mice were monitored at weekly intervals and showed no 
outward signs of illness or distress. Because the mice are raised and cared for in a sterile 
environment, there is little to no exposure to pathogens and disease, which may explain 
why there were no outward physical changes that appeared in these L2pB1 depleted 
mice. It is possible that if these mice had been exposed to pathogens or immune-
compromised situations, disease or outward physiological consequences could have been 
observed.  
Near complete depletion of L2pB1 cells has now been successfully performed.  
ELISA results of Anti-PC IgM support this observation and allows for approximate 
tracking of L2pB1 cell population levels. FACS analysis allowed for definitive 
confirmation of successful depletion of this cell subset. 
Our mouse model results were consistent with successful ablation of L2pB1 cells.  
However, when mice were sampled at 10 weeks following the 1st DT injection, there was 
evidence of partial regeneration of the L2pB1 cell population.  Complete depletion may 
not be possible in the bone marrow at current dosages, likely due to these progenitor cells 
not yet expressing their surface markers.  The small remaining number of L2pB1 cells 
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were likely able to partially restore the populations within the 10 weeks following 
injection.  Alternatively, there could be varying levels of DT receptor expression on the 
surface of the L2pB1 cells, which could result in small populations of the L2pB1 cells 
remaining in the system.  These remaining cells overtime, can self-renew and reestablish 
the L2pB1 cell population. This led to our decision to administer DT “boosters” at 4 
weeks following the 1st injection.  These boosters consisted of an additional 2 injections 
of 25ng DT per gram bodyweight at 10 weeks of age.  
Anti-PC IgM serum levels appear to be a good predictor of L2pB1 cell population 
health.  We were able to see that Anti-PC levels decreased to approximately 30% that of 
baseline levels in L2pB1 cell ablated mice.  This also confirms L2pB1 cells as being a 
significant contributor to total serum Anti-PC IgM. These serum Anti-PC IgM levels 
remained low throughout the 10-week time course for depleted mice.  However, there 
was a slight increase as time progressed likely due to regrowth of the L2pB1 cell 
population. Because of the low invasiveness of serum collection, Anti-PC IgM assays can 
be used to demonstrate changes in population or function of L2pB1 cells.   
Mice given HFD were seen to rapidly gain weight as expected.  However, 
differences in the two groups were observed.  Female mice gained weight at a 
significantly slower rate than male mice.  Because of this sex difference, male mice were 
used in the analysis of weight gain and blood glucose levels. Mice that had received DT 
appeared to show accelerated weight gain when compared to control groups. It is possible 
that L2pB1 cells could be involved in lipid transfer, storage and clean up and as a 
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protective agent curtailing rapid weight gain. Further samples need to be collected and 
mice will continue to be monitored to see if the trend continues.   
When GTT was performed, we observed a slight difference between the two 
groups.  The L2pB1 cell depleted groups showed significant higher baseline blood 
glucose levels and experienced a larger spike in their blood glucose readings compared to 
the control group.  However the two groups showed insignificant difference in 
subsequent recovery of glucose level. Because the DT groups also gained more weight 
than the control group, it is possible that the increased weight gain contributed to the 
impaired glucose tolerance of these mice.  Female mice GTT data were collected but 
were not included in our analysis because female mice GTTs did not follow the same 
trajectory as the male mice, likely due to the female mice gaining less weight than the 
males. Further studies are underway to investigate the effects at 10 weeks on HFD to 
visualize whether there is further separation in weight gain and glucose tolerance between 
these two groups.  
 
CONCLUSION 
  L2pB1 cells are a distinct subpopulation of B1a cells. We now possess a mouse 
model in which targeted depletion of L2pB1 cells can be achieved.  This novel technique 
allows for the elucidation of the physiological roles of these cells within various 
applications. In the future, this model can be used to investigate the involvement of 
L2pB1 cells in atherosclerosis, cancer, autoimmune disorders, etc.  For the first time, it 
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has been demonstrated that L2pB1 cells can be effectively depleted for 3-4 weeks at a 
time using a 25ng DT per gram bodyweight dosage for 4 days. 
L2pB1 cells have now been shown to play an important role in DIO and glucose 
intolerance.  Research is currently ongoing regarding the long-term effects of HFD in 
L2pB1 depleted mice.  We will continue to monitor these mice and will additionally 
perform insulin resistance tests as well as ELISA and FACS analysis to gain a better 
grasp of the roles these cells play in diseased states.  Preliminary results show a potential 
effect of these cells in DIO and glucose tolerance, however additional transgenic mice are 
required to establish a large enough sample size and statistical significance.   
There are still many questions that need to be answered regarding L2pB1 cells.  
The complete antibody and immune repertoire of these cells is still not fully understood 
and currently undergoing investigation. This small subpopulation of B cells appears to 
play a significant role in the immune system in murine models. Now, with this transgenic 
mouse model, L2pB1 cells can be ablated to varying degrees and various time points to 
continue to unlock the functions and mechanisms of these cells.  
 
METHODS 
Mice: 
Mice were purchased from Jackson Laboratory (Bar Harbor, MI). CD19-Cre (+/-) 
PD-L2-ZsG-TdT-DTR mice were developed (See Figure 1) and bred at the Boston 
University Medical Center Animal Facility.  Development and cell expression can be 
seen in Figure 1. Mice were housed in the pathogen free barrier facility at Boston 
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University Medical Campus in a temperature-controlled room with 12-hour light and 
dark cycles. All procedures involving animal use were approved by the Institutional 
Animal Care And Use Committee of the Boston University Medical Center.  
 
Mouse Tail Genotyping:  
 DNA Lysis Buffer (Antagen Pharmaceuticals, Inc., Boston, MA) was added to 
each tail sample after boiling them for 30 min. 1 ul of the lysate was then used for PCR 
amplification. Taq B and DNA Polymerase as well as 2 pairs of primers were heated to 
95 degrees for 5 minutes, 40 cycles of 95 degrees for 20 seconds, 60 degrees for 25 
seconds, and 72 degrees for 40 seconds.  The DNA was then visualized in 2% agarose gel 
electrophoresis.  
 
Fluorescent Imaging:   
To visually confirm the expression of ZsGreen and TdTomato, a peritoneal cell 
washout was performed to harvest L2pB1 cells. The Leica TCS SP5 microscope was 
used to visualize the fluorescence of the L2pB1 cells (Figure 2). Fluorescent images were 
taken at 63X oil-immersion objective.  
 
Depletion: 
 Following the DT injection protocol outlined in Demerick et al (2013), 25ng of 
DT (Sigma-Aldrich, St. Louis) per gram bodyweight was administered per injection to 
each mouse over 4 consecutive days. DT was diluted in PBS without calcium to 2µg 
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DT/mL, loaded into syringes to the appropriate volume allowing for 25ng DT/g 
bodyweight, and were injected into peritoneal cavity of 6-8week old mice. Control mice 
received PBS without calcium at a similar volume proportional to their bodyweight.  All 
precautions were taken to minimize risks for exposure. 
Blood samples were collected via lateral tail veins at the following time points: 
pre-injection, 4 days, 1 week, 3 weeks, 5 weeks, 7 weeks, 9 weeks, and 10 weeks after 
the 1st injection. Blood samples were stored at room temperature for 1 hr and then spun 
down twice at 10,000rpm for 5 min. Serum was isolated and stored at -20oC.   
For HFD mice, 4 weeks following the initial injection of DT, an additional 
booster of DT was administered and calculated accordingly with their current weight at 
that time. 
 
High Fat Diet:   
Mice were fed a high fat diet of 60% Fat/Cal (Harlan Laboratories, CA).  High fat 
diet was initiated immediately following the final injection of DT or PBS. Initial weights 
were recorded. After 3 weeks on a HFD, mice were weighed at 1-week intervals to track 
the rate at which they gained weight.   
 
ELISA:  
A standard curve for Anti-PC IgM was determined using Mouse Monoclonal 
Antibody Anti-Oxidized Phospholipid (Avanti Polar Lipids, AL).  96 well plates were 
coated with PC-BSA (BioSearch Technologies, CA) for 2 hr and then were washed 5 
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times for 2 min. Plates were then blocked overnight using a blocking buffer with 0.5% 
Tween.  The following day, plates were washed 5 times for 2 min with washing buffer as 
the standard curve was prepared. The standard curve used for Anti-PC IgM starting at 
1:5000 dilution and was triplicated. Serum was diluted at 1:50 with blocking buffer and 
was added to the plate in triplicates. Samples were incubated at 37oC for 1 hr and then 
washed 5 times for 2 min. Goat Anti-Mouse IgM HRP (Sigma, MO) was used as the 
secondary antibody and was added at 1:4000 dilution and incubated for 30 min at 37oC.  
Plates were then washed 10 times for 1 min. The plate was then incubated for 15 min 
with TMB Ultra substrate (Thermo Fischer, MA). A stopping solution was added and 
samples were read at 405 nm.   
 
Statistics: Statistical differences were calculated with Student's t-test method in Excel 
with p<0.05 accepted as the level of statistical significance.  
 
Glucose Tolerance Testing:   
Previous data suggest that mice begin to develop glucose intolerance as early as 7 
weeks on a HFD (data not shown).  Mice received a glucose tolerance test after 5.5 weeks 
on a HFD. Mice were separated into individual cages with only water and were fasted for 
6 hours prior to the GTT. D-Glucose (Sigma Cat. No. G-7528) was dissolved in MilliQ 
water to a concentration of 250 mg/mL. Baseline blood glucose levels were measured 
immediately before glucose was administered. The glucose solution was given to mice 
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via IP injection at a dosage of 1 mg glucose per gram bodyweight. When sampling blood, 
the first drop of blood was discarded at each time point and the second drop of blood was 
used to measure blood glucose levels. Blood was sampled at 15 min intervals via tail tip 
using a Contour glucometer and test strips.   
 
Tissues 
At week 10 after the first injection, the mice were sacrificed and fluids and tissues 
were collected for analysis. Blood was collected via cardiac puncture using a 25G needle. 
Peritoneal cell washout (PCW) was collected with HBSS with 2% FBS via syringe. The 
peritoneal cavity of each mouse was injected with 10 mL of the solution using a 27G 
needle and the sides of the mouse were massaged to maximize the number of cells 
collected. The PCW was then collected with a 23G needle and transferred to a tube to be 
counted and stained. The spleen and thymus were then collected and transferred to R10 
medium and were passed through a 70 nm strainer.  
All samples were spun in the centrifuge at 1200 rpm, supernatant was removed 
and cells were re-suspended in lysis buffer to lyse any red blood cells in the sample, cold 
PBS was added, and the cells were spun again.  Samples were then re-suspended in 200 
µL-1 mL of FACS buffer and cells were counted using a hemocytometer.  
 
Flow Cytometry:  
Cells suspended in FACS buffer were placed in a 96 well plate for staining. 30 µL 
of Fc Blocker (BioLegend, CA) were placed in each well and incubated on ice for 15 
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min.  Primary antibody mixtures and staining buffers were prepared and kept out of the 
light. Cells were then stained with PD-L2-PC, B220-PerCP-CY5.5, CD5-PECy7, CD19-
e450, CD11b APC Cy-7 (eBioscience, CA), Ghost Dye Violet 510 (Tonbo Biosciences, 
CA), and IgM-APC (eBioscience, CA). Plates were then centrifuged for 6 min at 1400 
rpm. The supernatant was removed and re-suspended in 150 µL of FACS buffer and 
centrifuged again. The secondary antibody (streptavidin-conjugates) was incubated with 
the plate on ice for 30 min.  The plate was then washed twice and samples were 
suspended in 150 µL of FACS Fix and added to FACS tubes and tubes were placed on 
ice until FACS was performed.  BD LSRII was used to collect FACS data, which were 
then analyzed using FlowJo software (TreeStar, OR).   
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● Employed search engine optimization techniques for the dealerships’ websites 
● Sole responsibility for purchasing and implementing online advertising campaigns 
through Google Adwords 
● Created and managed the dealerships’ social media sites.  
 
Designer of College Level Sports Medicine Textbook                   April 2012-May 2013 
● Worked with Berkeley Professor Dr. C.E. McLaughlin to create a digital textbook 
about sports medicine 
● Used the program iBooks Author to digitize, edit and design a textbook for the 
course that Dr. McLaughlin teaches at UC Berkeley and for the general public.  
● Responsible for annual updates to the textbook with new relevant information and 
research. 
 
University of California Berkeley       May 2012-June 2012  
     Undergraduate Student Instructor 
● Served as the undergraduate student instructor for Dr. C.E. McLaughlin’s IB 128: 
Sports Medicine course 
● Assisted students understanding of course material, reviewed topics and advised 
them on their research papers  
 
Home Health Care Provider                       1999-2009  
 
● Worked both formally for Solano County IHSS and informally for my 
grandmother.  
● Monitored her blood glucose and blood pressure levels 
● Administered insulin injections and medication 2-4 times daily while aiding in a 
physical therapy routine post-stroke 
● Assisted in bathing and changing her as well as cooking her meals and feeding her 
● Worked with healthcare professionals to develop a diet plan to maintain healthy 
blood glucose levels for her 
 
Research and Projects 
History of Science August-December 2010  
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Why was Gregor Mendel’s Research on the Hybridization of Peas Ignored During the 
Late 19th Century?  
● Conducted research into when Mendel’s work was published in relation to 
Darwin’s Origin of Species.  
● Concluded that the movement into biology emphasizing evolution overshadowed 
more specific and intricate concepts such as genetics.  
 
Environmental Toxicology January-May 2011  
Search Identification Research.  
Looked at Cadmium as a contaminate in a biosphere.  
● Conducted research into Cadmium leaching, chemical loading calculation and 
vertical sediment profile analysis. 
● Researched manufacturing practices and potential industrial Cadmium yields. 
● Used this along with data provided by my professor to determine the likely source 
of Cadmium contamination and analyze the bioavailability and toxicity data to 
determine the biological impact on the biota. 
 
Sports Medicine May-June 2011  
Ulnar Collateral Ligament Reconstruction in Baseball Pitchers.  
● Reviewed current notions of ligament reconstruction and its effect on a player’s 
ability to recover and return to play.  
● Analyzed five peer-reviewed articles from medical journals and analyzing the 
results of their studies.  
● Aggregated the specific studies into a broader analysis showing that ulnar 
collateral ligament reconstruction results in players returning to the same, or 
higher level of play within 2 years in 70%-90% of patients. 
  
Language Skills: Conversational Korean and Spanish  
 
 
 
